A Phase 2 interventional study of CD-LD IR and IPX203 180 mg in Parkinson's Disease, sponsored by Impax Laboratories, LLC. Completed at 11 sites in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2019-11-06.
Sponsored by Impax Laboratories, LLC (part of Amneal Pharmaceuticals, Inc.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Parkinson Disease by Amneal Pharmaceuticals, Inc. — 1 open to participants now, 1 under way, none of them phase 3. Parkinson Disease · Amneal Pharmaceuticals, Inc..
Among the 14 studies in Parkinson Disease by Amneal Pharmaceuticals, Inc., this one is the 11th largest by enrollment, is the only one that started in 2015, is one of 5 in phase 2, and was the 10th registered.
4,578 studies on the registry are indexed under Parkinson Disease; 1,087 are open to participants now.
Browse Parkinson Disease studies →1 of the 14 studies in Parkinson Disease by Amneal Pharmaceuticals, Inc. is open now, in 1 country. Recruiting first, the newest first:
Impax Laboratories, LLC · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 750 Parkinson Disease studies recruiting now, 312 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 190 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 7 · Phase 4 1
First in 2005; this study’s year is marked. 1 started in 2015.
This study's enrollment of 26 is below the median of 40 across 3,355 interventional studies indexed under Parkinson Disease.
Median enrollment 77 across the 14 interventional studies. Of the 13 that completed or were terminated, 9 (69%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Impax Laboratories, LLC, one of the names counted as Amneal Pharmaceuticals, Inc.. Under that name alone:
Impax Laboratories, LLC is the lead sponsor of 20 studies on the registry; 1 is open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 2 (25%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 14 studies in Parkinson Disease by Amneal Pharmaceuticals, Inc., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a randomized, open-label, rater-blinded, multicenter, 3-treatment, 3 period, single-dose crossover study. Approximately 51 qualified immediate-release (IR) CD-LD-experienced advanced Parkinson's disease patients will be randomized to 1 of 3 dosing sequences.
Objectives:
IPX203 contains two different drugs called levodopa and carbidopa in one capsule.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Male or female subjects diagnosed with idiopathic PD with motor complications, who are currently being treated chronically with stable regimens of CD-LD.
Requiring at least 400 mg but not more than 1600 mg LD per day during the waking hours; and at least 100 mg but not more than 250 mg LD from IR CD-LD for the first morning dose.
Dosing frequency of IR CD-LD of at least 4 times daily excluding nighttime dosing.
Have an average of at least 2 hours per day "off" time during the waking hours and at least 1 hour "off" time per day, based on the PD diary collected for 3 consecutive days prior to Visit 1.
Exclusion criteria:
Have used first morning dose of controlled-release (CR) CD-LD or Rytary for at least 4 weeks prior to Visit 1.
Female subjects who are currently breastfeeding or lactating.
Had prior functional neurosurgical treatment for PD (ablation or deep brain stimulation) or if such procedure(s) are planned or anticipated during the study period.
Allergic to study drugs
History of medical conditions or of a prior surgical procedure that would interfere with LD absorption, such as gastrectomy or small-bowel resection.
History of peptic ulcer disease or upper gastrointestinal hemorrhage.
History of narrow angle glaucoma.
History of myocardial infarction with residual atrial, nodal, or ventricular arrhythmias; neuroleptic malignant syndrome; or nontraumatic rhabdomyolysis.
History of psychosis.
Employees or family members of the Investigator, study site, or Sponsor.
Subjects who, in the opinion of the clinical investigator, should not participate in the study.
Based on clinical assessment, subject does not adequately comprehend the terminology needed to complete the PD diary.
Subject received a single dose of IPX203 180 mg and/or IPX203 270mg in Period 1, a single dose of CD-LD IR in Period 2, and a single dose of Rytary 145 mg and/or Rytary 195 mg in Period 3.
Drug: CD-LD IR · Drug: IPX203 180 mg · Drug: IPX203 270 mg · Drug: Rytary 195 mg · Drug: Rytary 145 mg
Subject received a single dose of a single dose of CD-LD IR in Period 1, a single dose of Rytary 145 mg and/or Rytary 195 mg in Period 2, and a single dose of IPX203 180 mg and/or IPX203 270mg in Period 3.
Drug: CD-LD IR · Drug: IPX203 180 mg · Drug: IPX203 270 mg · Drug: Rytary 195 mg · Drug: Rytary 145 mg
Subject received a single dose of a single dose of Rytary 145 mg and/or Rytary 195 mg in Period 1, a single dose of IPX203 180 mg and/or IPX203 270mg in Period 2, and a single dose of CD-LD IR in Period 3.
Drug: CD-LD IR · Drug: IPX203 180 mg · Drug: IPX203 270 mg · Drug: Rytary 195 mg · Drug: Rytary 145 mg
CD-LD IR containing 25 mg carbidopa and 100 mg levodopa
Also known as: Sinemet
IPX203 containing 45 mg carbidopa and180 mg levodopa
Also known as: CD-LD ER 180 mg
IPX203 containing 67.5 mg carbidopa and 270 mg levodopa
Also known as: CD-LD ER 270 mg
Rytary 48.75Mg-195Mg Extended-Release Capsule
Rytary 36.25Mg-145Mg Extended-Release Capsule
"Off" time per the Assessment of Subject's Motor State
Time frame: Up to 10 hours
Duration of effect estimated using the timepoint at which an improvement of at least 4 points in the MDS-UPDRS Part III score from predose is first observed and continuing until the timepoint at which the improvement is no longer observed
Time frame: Up to 10 hours
Change from predose value in the number of finger-taps at each timepoint
Time frame: Up to 10 hours
Number of Participants with Adverse Events
Time frame: Screening through end of study approximately 6 weeks per subject
Maximum concentration (Cmax)
Time frame: Up to 10 hours
Area under the curve (AUC)
Time frame: Up to 10 hours
Plan to share: No
No publications or documents are linked to this record.
The record gives a start of Nov 2015, a primary completion of Aug 2016 and a completion of Aug 2016. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: IPX203